The Mode of Inhibitor Binding to Peptidyl-tRNA Hydrolase: Binding Studies and Structure Determination of Unbound and Bound Peptidyl-tRNA Hydrolase from Acinetobacter baumannii

PLoS ONE

Volumn 8, Issue 7, 2013, Pages

  Kaushik, Sanket ^a   Singh, Nagendra ^a   Yamini, Shavait ^a   Singh, Avinash ^a   Sinha, Mau ^a   Arora, Ashish ^b   Kaur, Punit ^a   Sharma, Sujata ^a   Singh, Tej P ^a  

^a ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

^b CENTRAL DRUG RESEARCH INSTITUTE   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; CYTIDINE; HYDROLASE INHIBITOR; PEPTIDYL TRNA HYDROLASE; PEPTIDYL TRNA HYDROLASE INHIBITOR; RIBONUCLEASE; TRANSFER RNA; UNCLASSIFIED DRUG; URIDINE;

ACINETOBACTER BAUMANNII; AMINO ACID SEQUENCE; ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CRYSTALLIZATION; DRUG DESIGN; ENZYME ACTIVE SITE; ENZYME BINDING; ENZYME STRUCTURE; MOLECULAR CLONING; NONHUMAN; PROTEIN CONFORMATION; PROTEIN EXPRESSION; PROTEIN HYDROLYSIS; PROTEIN PROTEIN INTERACTION; RNA SYNTHESIS; STRUCTURE ANALYSIS; TRANSLATION REGULATION;

ACINETOBACTER BAUMANNII; CARBOXYLIC ESTER HYDROLASES; CATALYTIC DOMAIN; CRYSTALLOGRAPHY, X-RAY; CYTIDINE; ENZYME INHIBITORS; HYDROGEN BONDING; MODELS, MOLECULAR; MOLECULAR CONFORMATION; PROTEIN BINDING; PROTEIN STRUCTURE, SECONDARY; SPECTROMETRY, FLUORESCENCE; SURFACE PLASMON RESONANCE; URIDINE;

ACINETOBACTER BAUMANNII; NEGIBACTERIA;

EID: 84879760460     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0067547     Document Type: Article

References (45)

1. Das G, Varshney U, (2006) Peptidyl tRNA hydrolase and its critical role in protein biosynthesis. Microbiology 152: 2191-2195.
2. Singh NS, Varshney U, (2004) A physiological connection between tmRNA and peptidyl-tRNA hydrolase functions in Escherichia coli. Nucleic Acids Res 32: 6028-6037.
3. Ling J, Roy H, Ibba M, (2007) Mechanism of tRNA-dependent editing in translational quality control. Proc Natl Acad Sci U S A 104: 72-78.
4. Schmitt E, Mechulam Y, Fromant M, Plateau P, Blanquet S, (1997) Crystal structure at 1.2 Å resolution and active site mapping of Escherichia coli peptidyl-tRNA hydrolase. EMBO J 16: 4760-4769.
5. Menninger JR, (1979) Accumulation of peptidyl tRNA is lethal to Escherichia coli. J Bacteriol 137: 694-696.
6. De-Pereda JM, Waas WF, Jan Y, Ruoslahti E, Schimmel P, et al. (2004) Crystal structure of a human peptidyl-tRNA hydrolase reveals a new fold and suggests basis for a bifunctional activity. J Biol Chem 279: 8111-8115.
7. Oncul O, Keskin O, Acar HV, Kucukardali Y, Evrenkaya R, et al. (2002) Hospital-acquired infections following the 1999 Marmara earthquake. J Hosp Infect 51: 47-51.
8. Zeana C, Larson E, Sahni J, Bayuga SJ, Wu F, et al. (2003) The epidemiology of multidrug-resistant Acinetobacter baumannii: does the community represent a reservoir? Infect Control Hosp Epidemiol 24: 275-279.
9. Towner KJ, (2009) Acinetobacter: an old friend, but a new enemy J Hosp Infec. 73: 355-363.
10. Goodhart GL, Abrutyn E, Watson R, Root RK, Egert J, (1977) Community acquired Acinetobacter calcoaceticus var anitratus pneumonia. JAMA 238: 1516-1518.
11. Hsueh PR, Teng LJ, Chen CY, Chen WH, Yu C, et al. (2002) Pandrug-resistant Acinetobacter baumannii causing nosocomial infections in a university hospital, Taiwan. Emerg Infect Dis 8: 827-832.
12. Lee K, Yong D, Jeong SH, Chong Y, (2011) Multidrug-Resistant Acinetobacter spp.: Increasingly Problematic Nosocomial Pathogens. Yonsei Med J 52: 879-891.
13. Pachon J, Vila J, (2009) Treatment of multiresistant Acinetobacter baumannii infections. Curr Opin Investig Drugs 10: 150-156.
14. Brisse S, Milatovic D, Fluit AC, Kusters K, Toelstra A, et al. (2000) Molecular surveillance of European Quinolone-resistant clinical isolates of Pseudomonas aeruginosa and Acinetobacter spp. using automated ribotyping. J Clin Microbiol 38: 3636-3645.
15. Endimiani A, Hujer KM, Hujer AM, Kurz S, Jacobs MR, et al. (2011) Are we ready for novel detection methods to treat respiratory pathogens in hospital-acquired pneumonia? Clin Infect Dis 52: S373-S383.
16. Anstey NM, Currie BJ, Hassell M, Palmer D, Dwyer B, et al. (2002) Community-acquired bacteremic Acinetobacter pneumonia in tropical Australia is caused by diverse strains of Acinetobacter baumannii, with carriage in the throat of at-risk groups. J Clin Microbiol 40: 685-686.
17. Chen MZ, Hsueh PR, Lee LN, Yu CJ, Yang PC, et al. (2001) Severe community-acquired pneumonia due to Acinetobacter baumannii. Chest 120: 1072-1077.
18. Seifert H, Baginski R, Schulze A, Pulverer G, (1993) Antimicrobial susceptibility of Acinetobacter species. Antimicrob Agents Chemother 37: 750-753.
19. Zhou H, Zhang T, Yu D, Pi B, Yang Q, et al. (2011) Genomic Analysis of the Multidrug-Resistant Acinetobacter baumannii Strain MDR-ZJ06 Widely Spread in China. Antimicrob Agents Chemother 55: 4506-4512.
20. Henry R, Vithanage N, Harrison P, Seemann T, Coutts S, et al. (2012) Colistin-resistant, lipopolysaccharide-deficient Acinetobacter baumannii responds to lipopolysaccharide loss through increased expression of genes involved in the synthesis and transport of lipoproteins, phospholipids, and poly-β-1,6-N-Acetylglucosamine. Antimicrob Agents Chemother 56: 59-69.
21. Lim TP, Tan TY, Lee W, Sasikala S, Tan TT, et al. (2011) In-Vitro Activity of Polymyxin B, Rifampicin, Tigecycline Alone and in Combination against Carbapenem-Resistant Acinetobacter baumannii in Singapore. PLoS One 6: 184-185.
22. Selvaraj M, Roy S, Singh NS, Sangeetha R, Varshney U, et al. (2007) Structural plasticity and enzyme action: crystal structures of mycobacterium tuberculosis peptidyl-tRNA hydrolase. J Mol Biol 372: 186-193.
23. Kumar A, Singh N, Yadav R, Kumar RP, Sharma S, et al. (2012) Crystal structure of peptidyl-tRNA hydrolase from Mycobacterium smegmatis reveals novel features related to enzyme dynamics. Int J Biochem Mol Biol 23: 58-69.
24. Hughes RC, McFeeters H, Coates L, McFeeters RL, (2012) Recombinant production, crystallization and X-ray crystallographic structure determination of the peptidyl-tRNA hydrolase of Pseudomonas aeruginosa. Acta Crystallogr Sect F Struct Biol Cryst Commun 68: 1472-1476.
25. Ito K, Murakami R, Mochizuki M, Qi H, Shimizu Y, et al. (2012) Structural basis for the substrate recognition and catalysis of peptidyl-tRNA hydrolase. Nucleic Acids Res 40: 10521-10531.
26. Charland MB (1995) SigmaPlot for Scientists, Version 8.0, Wm. C. Brown Communications, Inc., Dubuque, IA.
27. Fan JC, Chen X, Wang Y, Fan CP, Shang ZC, (2006) Binding interactions of pefloxacin mesylate with bovine lactoferrin and human serum albumin. J Zhejiang Univ Sci B 7: 452-458.
28. Otwinowski Z, Minor W, (1997) Processing of X-ray diffraction data collected in oscillation mode. Methods Enzymol 276: 307-326.
29. Matthews BW, (1968) Solvent Content of Protein Crystals. J Mol Biol 33: 491-496.
30. Murshudov GN, Skubak P, Lebedev AA, Pannu NS, Steiner RA, et al. (2011) REFMAC5 for the refinement of macromolecular crystal structures. Acta Crystallogr D Biol Crystallogr. 67: 355-367.
31. Emsley P, Cowtan K, (2004) Coot: model-building tools for molecular graphics. Acta Crystallogr D Biol Crystallogr. 60: 2126-2132.
32. Jones TA, Zou JY, Cowan SW, Kjeldgaard M, (1991) Improved methods for building protein models in electron density maps and the location of errors in these models. Acta Crystallogr A 47: 110-119.
33. Laskowski RA, MacArthur MW, Moss DS, Thornton JM, (1993) PROCHECK: a program to check stereo chemical quality of protein structures. J Appl Crystallogr 26: 283-291.
34. Davis IW, Murray LW, Richardson JS, Richardson DC, (2004) MOLPROBITY: structure validation and all-atom contact analysis for nucleic acids and their complexes. Nucleic Acids Res 1: 615-619.
35. Ramachandran GN, Sasisekaran V, (1968) Conformation of polypeptides and proteins. Adv Protein Chem. 23: 283-438.
36. Chapman MS, (1995) Restrained real-space macromolecular atomic refinement using a new resolution-dependent electron-density function. Acta Crystallogr A Biol 51: 69-80.
37. Tickle IJ, (2012) Statistical quality indicators for electron-density maps. Acta Crystallogr D Biol Crystallogr 68: 454-467.
38. Krissinel E, Henrick K, (2007) Inference of macromolecular assemblies from crystalline state. J Mol Biol 372: 774-779.
39. Kushwaha GS, Yamini S, Kumar M, Sinha M, Kaur P, et al. (2012) First structural evidence of sequestration of mRNA cap structures by type 1 ribosome inactivating protein from Momordica balsamina. Proteins 81: 896-905.
40. Kushwaha GS, Pandey N, Sinha M, Singh SB, Kaur P, et al. (2012) Crystal structures of a type-1 ribosome inactivating protein from Momordica balsamina in the bound and unbound states. Biochim Biophys Acta 1824: 679-691.
41. Singh N, Jabeen T, Pal A, Sharma S, Perbandt M, et al. (2008) Crystal structures of the complexes of a group IIA phospholipase A2 with two natural anti-inflammatory agents, anisic acid, and atropine reveal a similar mode of binding. Proteins 64: 80-100.
42. Singh N, Kumar RP, Kumar S, Sharma S, Mir R, et al. (2009) Simultaneous inhibition of anti-coagulation and inflammation: crystal structure of phospholipase A2 complexed with indomethacin at 1.4 A resolution reveals the presence of the new common ligand-binding site. J Mol Recognit 6: 437-445.
43. Jabeen T, Singh N, Singh RK, Sharma S, Somvanshi RK, et al. (2005) Non-steroidal anti-inflammatory drugs as potent inhibitors of phospholipase A2: structure of the complex of phospholipase A2 with niflumic acid at 2.5 Angstroms resolution. Acta Crystallogr D Biol Crystallogr 12: 1579-1586.
44. Singh RK, Ethayathulla AS, Jabeen T, Sharma S, Kaur P, et al. (2005) Aspirin induces its anti-inflammatory effects through its specific binding to phospholipase A2: crystal structure of the complex formed between phospholipase A2 and aspirin at 1.9 angstroms resolution. J Drug Target 2: 113-119.
45. Singh G, Jasti J, Saravanan K, Sharma S, Kaur P, et al. (2005) Crystal structure of the complex formed between a group I phospholipase A2 and a naturally occurring fatty acid at 2.7 A resolution. Protein Sci 2: 395-400.